ASH 2024 Myeloma Report | Abstract Finder

Abstract Number: 362 – Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Presenter: Sonja Zweegman, MD, PhDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment DecisionsDate & Time: Saturday, December 7, 2024 4:15 PM–4:30 PMLocation: San...

Abstract Number: 361 – Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

Presenter: Panagiotis Malandrakis, MDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment DecisionsDate & Time: Saturday, December 7, 2024 4:00 PM–4:15 PMLocation: San...

Abstract Number: 356 – Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN+ Preclinical Model of Multiple Myeloma

Presenter: Erin W Meermeier, PhDSession: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell DisordersDate & Time: Saturday, December 7, 2024 4:15 PM–4:30 PMLocation:...

Abstract Number: 284 – Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Presenter: Anna FleischerSession: 907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple MyelomaDate & Time: Saturday, December 7, 2024 2:15 PM–2:30 PMLocation: Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego...

Abstract Number: 258 – Daratumumab-Based Quadruplet Versus Triplet Induction Regimens in Frontline Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Presenter: Joao Tadeu Damian Souto Filho, MD, PhDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad TherapiesDate & Time: Saturday, December 7, 2024 3:15 PM–3:30 PMLocation: Pacific...

Abstract Number: 252 – Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma

Presenter: Palak BajajSession: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma OutcomesDate & Time: Saturday, December 7, 2024 3:15 PM–3:30 PMLocation: San Diego Ballroom AB (Marriott Marquis...

« Older Entries

Next Entries »

Abstract Number: 361 – Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

Abstract Number: 356 – Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN+ Preclinical Model of Multiple Myeloma

Abstract Number: 284 – Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Abstract Number: 258 – Daratumumab-Based Quadruplet Versus Triplet Induction Regimens in Frontline Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Abstract Number: 252 – Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma

Recent Posts

Recent Comments

Archives

Categories

Meta